Eli Lilly and Company Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (43)

Latest Posts

About This Stock More About This Stock
Stocks Going Ex Dividend The Third Week Of November 2017
Article By: Fred Fuld
Saturday, November 11, 2017 6:00 PM EST
Here is our latest update on the stock trading technique called ‘Buying Dividends,’ also commonly referred to as ‘Dividend Capture.’ This is the process of buying stocks before the ex dividend date and selling the stock shortly after the ex date.
In this article: BUD, ED, HBI, LLY, TGT
Lilly (LLY) Beats On Q3 Earnings, Explores Sale Of Elanco
Article By: Zacks Investment Research
Tuesday, October 24, 2017 10:53 AM EST
Eli Lilly and Company reported third-quarter 2017 adjusted earnings per share of $1.05, which beat the Zacks Consensus Estimate of $1.03 per share by 1.9%.
In this article: LLY Also: INCY, SNY, BIIB
What To Watch In Eli Lilly Earnings Report
Article By: The Fly
Tuesday, October 24, 2017 3:37 AM EST
Eli Lilly is scheduled to report results of its third fiscal quarter before the market open today, Tuesday, with a conference call scheduled for 9:00 am EDT. Consensus estimates for FY17 EPS is 4.16.
In this article: LLY Also: RHHBY, INCY
How To Get Involved In The Drug Trade (It’s Not What You Think)
Article By: David Zarling
Saturday, October 14, 2017 11:58 AM EST
Eli Lilly & Co. (LLY), one of the world’s largest drug manufacturers, has seen its stock go nowhere for 2 years. This after Lilly was up over 350% from the bottom in 2009 through September 2015. Last week, it broke out of the 2-year base.
In this article: LLY
5 Pharma & Biotech Stocks That Could Be Big Winners In Q3 Earnings
Article By: Arpita Dutt
Tuesday, October 10, 2017 4:34 PM EST
Pharma and biotech stocks started 2017 on a strong note with this part of the market remaining in favor as the year progresses. So far this year, the Nasdaq Biotechnology Index is up 25.6%.
In this article: LLY, MRK, PFE, BIIB, VRTX Also: NVS, GILD


Latest Tweets for $LLY

No tweets yet!